Adagene (ADAG) vs MacroGenics (MGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
MacroGenics (MGNX) has outperformed Adagene (ADAG) over the past year, gaining 40.0% versus a loss of 2.2%. Over five years, ADAG leads with a -79.7% price change compared with -89.6% for MGNX. MacroGenics is the larger company by market cap ($125.3 million vs $118.2 million), about 1.1 times the size, while Adagene is growing revenue faster (+7332.8% vs -0.3%).
MacroGenics converts more of its revenue into profit, with a net margin of -49.9% versus -229.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ADAG | MGNX |
|---|---|---|
| Share price | $1.76 | $1.96 |
| Market cap | $118.17M | $125.26M |
| 1-day change | -12.44% | -1.01% |
| YTD return | -6.88% | +21.74% |
| 1-year return | -2.22% | +40.00% |
| 5-year return | -79.75% | -89.56% |
| EPS (TTM) | $-0.37 | $-2.30 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $7.67M | $149.50M |
| Revenue growth (YoY) | +7332.76% | -0.31% |
| Net income (latest FY) | $-17.61M | $-74.62M |
| Gross margin | — | 100.00% |
| Operating margin | -279.48% | -48.72% |
| Net margin | -229.56% | -49.91% |
| 52-week high | $4.85 | $5.08 |
| 52-week low | $1.27 | $1.32 |
| Distance from 52-week high | -63.71% | -61.42% |
| Analyst consensus | none | buy |
| Avg. price target upside | +463.07% | +308.16% |
| Average volume | 348.81K | 747.02K |
| Shares outstanding | 67.14M | 63.91M |
| Employees | 128 | 293 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MGNX has outperformed ADAG by 42.2 percentage points over the past year.
- MacroGenics is more profitable, keeping -49.9 cents of every revenue dollar as net income versus -229.6 cents for Adagene.
- Adagene grew revenue faster in its latest fiscal year (+7332.76% vs -0.31%).
About Adagene
ADAG stock →Adagene Inc., a clinical stage biotechnology company, engages in the research, development, and production of monoclonal antibody drugs for cancers in the People's Republic of China. Its lead product candidate is the ADG126, a masked fully-human anti-CTLA-4 mAb which is in phase 1b/2 clinical development for the treatment of cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 128 employees
About MacroGenics
MGNX stock →MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule that targets an undisclosed antigen expressed across several solid tumors, which is in preclinical trials.
Health Care · Biotechnology: Pharmaceutical Preparations · 293 employees
ADAG vs MGNX FAQ
Which is bigger, Adagene or MacroGenics?
MacroGenics (MGNX) is larger, with a market capitalization of $125.26M compared with $118.17M for Adagene (ADAG).
Which stock has performed better over the past year, ADAG or MGNX?
MGNX returned +40.00% over the past 12 months, compared with -2.22% for ADAG (price return, excluding dividends). Past performance does not predict future results.
Are Adagene and MacroGenics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.